Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.11)
# 4,114
Out of 4,786 analysts
4
Total ratings
25%
Success rate
-33.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $27.00 | +237.04% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $0.98 | +1,124.61% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $89.76 | +24.78% | 1 | Oct 28, 2022 |
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $27.00
Upside: +237.04%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $0.98
Upside: +1,124.61%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $89.76
Upside: +24.78%